Loading…
← CockpitCompetitor Analysis › 127120.KS JS Link, Inc.Open in the cockpit ↗

JS Link, Inc.127120.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical/Nursing Services
Momentum laggard 4
Mkt cap
$458M
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$2.01M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-21.4 pp
WACC 7.3%
Hurdle
n/a
no reverse DCF
Close · KRW₩15,350
1D-6.5%
1W-22.5%
1M-17.5%
3M-62.1%
6M-62.1%
YTD-14.0%
1Y-25.7%
ATR %12.2%
52w lowhigh69.2% off high

What JS Link does

Employees: 139

JS Link at a glance

Size JS Link (127120.KS) is a South Korea Health Care company (Medical/Nursing Services) with a market value of $458M, the 366th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩15,350 on 18 Nov 2026.

Performance Over six months the shares fell 62.1%, against -3.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 38.8% over the last twelve months (peer median +5.1%); the operating margin is -83.4% (peer median 8.4%).

Valuation It trades at 25.2× enterprise value to sales against a peer median of 1.5× (most expensive of 21).

Capital Return on invested capital runs 21.4 points below its cost of capital (7.3% WACC).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 98127120.KS 43
Six months, rebased to 100: JS Link against the median of its 20 peers (local-currency closes).

JS Link financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩22.4B₩19.3B₩15.9B₩21.9B₩17.0B
Revenue growth—+21%-28%+29%—
Gross profit₩2.56B₩2.28B₩1.84B₩4.60B₩2.36B
EBITDA-₩12.9B-₩12.5B-₩7.47B-₩2.71B-₩3.46B
Net income-₩11.2B-₩16.4B-₩10.8B-₩5.60B-₩7.78B
Free cash flow-₩47.9B-₩53.4B-₩23.5B-₩7.91B-₩4.02B
Capital expenditure₩20.7B₩44.1B₩16.7B₩2.89B₩5.09B
Total debt₩56.4B₩43.3B₩19.1B₩4.32B₩6.09B

Quarterly statements and history in the cockpit →

JS Link competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%SRTAACLIDX301060JSLL9860DNAM12AYUPA300642NIOXWELLAUNAFLGTNEPHROPLUSGMRSDRAGARWQ127120.KS6-month return →1-month return →
Up and to the right = strong over both horizons. JS Link is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%10×20×SRTAACLIDX301060JSLL9860DNAM12AYUPA300642STLNNIOXAUNANEPHROPLUSDRAGARWQ1951127120.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JS Link is the large dot.

JS Link competitors and peer comparison

How JS Link compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JS Link against its 20 peers (data as of 18 Nov 2026)
Measure127120.KSPeer medianRank in peer set
1-month return-17.5%-6.8%7th lowest of 21
6-month return-62.1%-3.5%lowest of 20
Distance from 52-week high-69.2%-26.3%lowest of 21
Revenue growth (TTM)+38.8%+5.1%2nd highest of 21
Operating margin-83.4%8.4%2nd lowest of 21
EV / Sales25.2×1.5×most expensive of 21
ROIC minus cost of capital-21.4 pp-0.3 pp5th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
JS Link 127120.KSSouth Korea$458M-62%+39%-83%25.2×n/an/a
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%1.4×n/an/a
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%1.3×4.3%+2.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%1.5×7.8%+17.7%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%2.3×5.9%+3.2%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%4.0×7.3%+42.6%
ADICON 9860.HKHong Kong$393M+5%+1%4%1.3×12.3%-1.5%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%6.5×n/an/a
M1 Kliniken M12.DEGermany$368M+1%-28%13%1.2×-5.3%+17.9%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%0.4×-14.9%+9.6%
Tellgen 300642.SZChina$328M-11%+5%8%5.2×18.8%-5.8%
Oncology Institute STLNUnited States$326Mn/a+35%-3%0.6×5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%4.9×3.4%+15.3%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%1.2×10.1%+94.5%
Auna AUNAUnited States$309M-5%+17%13%1.0×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%2.4×-13.8%+15.4%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%1.2×n/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%5.6×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%0.9×-19.6%-4.0%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%5.5×19.6%+27.5%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%2.8×17.8%+12.4%

Questions

Which companies are JS Link's closest peers?
The cockpit's peer set: Strata Critical Medical (SRTA), Australian Clinical Labs (ACL.AX), Integral Diagnostics (IDX.AX), Shanghai Labway Clinical Laboratory (301060.SZ), Jeena Sikho Lifecare (JSLL.NS), ADICON (9860.HK), Ginkgo Bioworks (DNA), M1 Kliniken (M12.DE).
Is JS Link expensive compared with its peers?
On ev / sales it trades at 25.2× against a peer median of 1.5×, most expensive of 21 in its peer set.
How has JS Link stock performed?
Over six months to 18 Nov 2026 the shares returned -62.1% against -3.5% for the median peer; over one year -25.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.